Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Pancreatic Neoplasms × Afatinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3 Adenocarcinoma 2 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Colorectal Neoplasms 1 Colonic Neoplasms 1

Interventions

zenocutuzumab 1 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pembrolizumab 1 olaparib 1 entrectinib 1 adagrasib 1 Cetuximab 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Mirati Therapeutics Inc.

Phase 1/2 Active not recruiting

731 enrolled 2 FDA

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡